Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZAAX is a standardized tomato extract (STE) developed as a dietary supplement and nutraceutical with antiplatelet and antihypertensive properties. It is primarily investigated by Beata Krasinska and colleagues at the Poznan University of Medical Sciences for its potential as an alternative to acetylsalicylic acid (aspirin) in patients with primary hypertension and high cardiovascular risk, particularly those with obesity. The extract exerts its effects through a multifactorial mechanism, inhibiting platelet aggregation mediated by ADP, thromboxane, collagen, von Willebrand factor, and thrombin. Unlike aspirin, its antiplatelet effects are reversible and do not significantly increase the risk of major bleeding, making it a potentially safer option for primary prevention in high-risk individuals.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ZAAX.